{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:13:57Z","timestamp":1793945637829,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005930","name":"ASCRS Research Foundation","doi-asserted-by":"publisher","award":["2023JCJQJJ0731"],"award-info":[{"award-number":["2023JCJQJJ0731"]}],"id":[{"id":"10.13039\/100005930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L222075"],"award-info":[{"award-number":["L222075"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.virol.2024.110125","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:41:24Z","timestamp":1716493284000},"page":"110125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge"],"prefix":"10.1016","volume":"596","author":[{"given":"Yuying","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoya","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengran","family":"Chuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.virol.2024.110125_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14760584.2019.1622419","article-title":"Challenges in estimating influenza vaccine effectiveness","volume":"18","author":"Ainslie","year":"2019","journal-title":"Expert Rev. Vaccines"},{"issue":"10101","key":"10.1016\/j.virol.2024.110125_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a Mrna rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110125_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-Methylpseudouridine-Incorporated Mrna outperforms pseudouridine-incorporated Mrna by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Contr. Release"},{"issue":"6622","key":"10.1016\/j.virol.2024.110125_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified Mrna vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110125_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trsl.2021.12.006","article-title":"An Mrna vaccine to prevent genital herpes","volume":"242","author":"Awasthi","year":"2022","journal-title":"Transl. Res."},{"issue":"6","key":"10.1016\/j.virol.2024.110125_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of Mrna vaccines and Immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.virol.2024.110125_bib8","unstructured":"CDC. 2022-2023 U.S. Flu Season: Preliminary in-Season Burden Estimates [updated March 24, 2023]. Available from: https:\/\/www.cdc.gov\/flu\/about\/burden\/preliminary-in-season-estimates.htm?msclkid=ffacd4dbce3c11eca39a9738d63f1f64.."},{"key":"10.1016\/j.virol.2024.110125_bib9","unstructured":"Cdc Seasonal Flu Vaccine Effectiveness Studies.."},{"issue":"1","key":"10.1016\/j.virol.2024.110125_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-021-00420-6","article-title":"Development of multivalent Mrna vaccine candidates for seasonal or pandemic influenza","volume":"6","author":"Chivukula","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.virol.2024.110125_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","article-title":"Double-layered protein nanoparticles induce broad protection against divergent influenza a viruses","volume":"9","author":"Deng","year":"2018","journal-title":"Nat. Commun."},{"issue":"7876","key":"10.1016\/j.virol.2024.110125_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of Mrna vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110125_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus Mrna vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.virol.2024.110125_bib15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified Mrna influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.virol.2024.110125_bib16","doi-asserted-by":"crossref","first-page":"e1644","DOI":"10.1016\/S2214-109X(21)00455-1","article-title":"Respiratory syncytial virus: promising progress against a leading cause of pneumonia","volume":"9","author":"Ginsburg","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.virol.2024.110125_bib17","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"50","key":"10.1016\/j.virol.2024.110125_bib18","doi-asserted-by":"crossref","first-page":"20248","DOI":"10.1073\/pnas.1320524110","article-title":"Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and Ns1 proteins","volume":"110","author":"Heaton","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2024.110125_bib19","article-title":"The race toward a universal influenza vaccine: front runners and the future directions","author":"Hu","year":"2022","journal-title":"Antivir. Res."},{"issue":"18","key":"10.1016\/j.virol.2024.110125_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00593-21","article-title":"Structure, immunogenicity, and conformation-dependent receptor binding of the postfusion human metapneumovirus F protein","volume":"95","author":"Huang","year":"2021","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2024.110125_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of rna recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of Rna","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.virol.2024.110125_bib22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza virus: dealing with a drifting and shifting pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/j.virol.2024.110125_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled Mrna vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7936","key":"10.1016\/j.virol.2024.110125_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/d41586-022-03590-y","article-title":"Can Mrna vaccines transform the fight against Ebola?","volume":"611","author":"Kozlov","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.virol.2024.110125_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza a virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.virol.2024.110125_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111951","article-title":"Mutational fitness landscape of human influenza H3n2 neuraminidase","volume":"42","author":"Lei","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.virol.2024.110125_bib27","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of Mrna structure, stability, and translation for Rna-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.virol.2024.110125_bib28","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped Mrna","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"45","key":"10.1016\/j.virol.2024.110125_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2206333119","article-title":"Assessment of a quadrivalent nucleoside-modified Mrna vaccine that protects against group 2 influenza viruses","volume":"119","author":"McMahon","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"23","key":"10.1016\/j.virol.2024.110125_bib30","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after Bnt162b2 Mrna vaccine against covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.virol.2024.110125_bib32","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1038\/s41591-021-01602-4","article-title":"Mrna vaccines offer hope for hiv","volume":"27","author":"Morris","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.virol.2024.110125_bib33","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1073\/pnas.1916131117","article-title":"Host protein glycosylation in nucleic acid vaccines as a potential hurdle in vaccine design for nonviral pathogens","volume":"117","author":"Ozdilek","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.virol.2024.110125_bib34","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/s41467-022-32149-8","article-title":"Development of a pentavalent broadly protective nucleoside-modified Mrna vaccine against influenza B viruses","volume":"13","author":"Pardi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110125_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28572","article-title":"Mrna vaccines: the future of prevention of viral Infections?","author":"Rzymski","year":"2023","journal-title":"J. Med. Virol."},{"issue":"16","key":"10.1016\/j.virol.2024.110125_bib36","doi-asserted-by":"crossref","first-page":"8728","DOI":"10.3390\/ijms22168728","article-title":"Immune prophylaxis and therapy for human cytomegalovirus infection","volume":"22","author":"Struble","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.virol.2024.110125_bib37","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s13346-020-00725-4","article-title":"Optimization of an Mrna vaccine assisted with cyclodextrin-polyethyleneimine conjugates","volume":"10","author":"Tan","year":"2020","journal-title":"Drug delivery and translational research"},{"issue":"5","key":"10.1016\/j.virol.2024.110125_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02127-19","article-title":"Nanopore sequencing reveals novel targets for detection and surveillance of human and avian influenza a viruses","volume":"58","author":"Yip","year":"2020","journal-title":"J. Clin. Microbiol."},{"issue":"47","key":"10.1016\/j.virol.2024.110125_bib39","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3n2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224001466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224001466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:46:44Z","timestamp":1754405204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224001466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":36,"alternative-id":["S0042682224001466"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110125","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110125"}}